期刊文献+

血清CA125检测对鉴别盆腔良、恶性包块的诊断意义 被引量:19

下载PDF
导出
摘要 目的:探讨血清中糖类抗原-125(CA125)的检测水平对盆腔包块性质判定的诊断价值。方法:对我院2009年1月至2012年8月经超声诊断为盆腔包块需手术切除而住院的389例患者术前采用放射免疫分析法进行血清CA125检测,并与正常健康体检者作对照。CA125>35 U/mL为阳性,将其结果与手术切除标本的病理诊断结果进行比较分析。结果:良性肿瘤365例,CA125平均值(71.92±6.36)U/mL,其中子宫肌瘤127例,子宫腺肌病141例,卵巢(冠)囊肿53例,卵巢子宫内膜异位囊肿19例,盆腔炎性疾病9例,异位妊娠16例。恶性肿瘤24例,CA125平均值(374.43±5.67)U/mL,其中卵巢恶性肿瘤23例,宫颈癌1例。正常健康体检者39例,CA125平均值(28.61±2.10)U/mL。恶性肿瘤较良性肿瘤、健康体检者血清CA125值明显升高(P<0.01)。良性肿瘤中子宫腺肌病血清CA125值较其他肿瘤、健康体检者明显升高但仍然比恶性肿瘤低。结论:血清CA125在各种盆腔包块中均有升高,恶性肿瘤中显著升高。结论:血清CA125的检测有助于临床鉴别盆腔包块的良恶性,对确定治疗方案有一定的指导意义。
作者 尧明凤 汤宏
出处 《实用医学杂志》 CAS 北大核心 2014年第10期1615-1616,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献5

二级参考文献11

  • 1杨永彬,徐伟,陈建利,万小平.卵巢癌肿瘤标志物研究进展[J].国外医学(妇产科学分册),2004,31(4):229-232. 被引量:24
  • 2Pickle LW, Hao Y, Jemal A,et al.A new method of esti2matingUnited States and state -level cancer incidencecounts for thecurrent calendar year [ J].CA Cancer J Clin,2007,57 (1) : 30-42.
  • 3Lorkova L, Pospisilova J, Lacheta J, et al. Decreasedconcentrations of retinol-binding protein 4 in sera of epithelialovarian cancer patients : A potential biomarker identified byproteomics[J]. Oncol Rep,2012,27(2) :318-324.
  • 4Heintz AP,Odicino F,Maisonneuve P,et al.Carcinoma of theovary.FIGO 26th Annual Report on the Results of Treatment inGynaecological Cancer[J].Int J Gynaecol Obstet,2006,95 Suppl1:S161-S192.
  • 5Sklmisddttir I,Sorbe B.Prognosti factor for surgical outcome andsurvival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma [ J ].Int J Oncol, 2007,30 ( 3):727-734.
  • 6Benjapibal M,Neungton C.Pre-operative prediction of serumCA125 level in women with ovarian masses [J].J Med Assoc Thai,2007,90(10):1986-1991.
  • 7Moore RG,MacLaughlan S,Bast RC Jr.Current state of biomarkerdevelopment for clinical application in epithelial ovarian cancer[J]. Gynecol Oncol,2010,116(2) : 240-245.
  • 8Hellstrom I, Haycraft J, Hayden -Ledbetter M , et ai.The HE4(WFDC2) protein is a biomarker for ovarian carcinoma [J].Cancer Res, 2003,63(13): 3695-3700.
  • 9Moorer HG, Brown AK, Miller MC,et ai.The use of multiplenovel tumor biomarkers for the detection of ovarian carcinomain patients with a pelvic mass[J]. Gynecol Oncol,2008,108(2):402-408.
  • 10Aigner E,Bachofner N,Klein K,et al.Retinol-binding protein 4in polycystic ovary syndrome-association with steroid hormonesandresponse to pioglitazone treatment[J]J Clin Endocrinol Metab,2009,94(4):1229-1235.

共引文献12

同被引文献205

  • 1宫颈癌及癌前病变规范化诊疗指南(试行)[J].中国医学前沿杂志(电子版),2013,5(8):40-49. 被引量:239
  • 2冯蕾 庄敏.宫颈癌新辅助化疗的护理.现代医院,2009,9(1):165-165.
  • 3Donach M, Yu Y, Artioli G, et al. Combined use of biomarkers for detection of ovarian cancer in high-risk women [J]. Tumor Biol, 2010, 31(3): 209-215.
  • 4SPAHN M,WEISS C,BADER P,et al.The role of exenterative surgery and urinary diversion in persistent or locally recurrent gynecological malignancy:complications and survival[J].Urol Int,2010,85(1):16-22.
  • 5MONTAGNANA M,LIPPI G,RUZZENENTE O,et al.The utility of serum human epididymis protein 4(HE4)in patients with a pelvic mass[J].Clin Lab Anal,2009,23(5):331-335.
  • 6ANASTASI E,MARCHEI G,VIGGIANI V,et al.HE4:a new potential early biomarker for the recurrence of ovarian cancer[J].Tumour Biol,2010,31(2):113-119.
  • 7Barrow H,Tam B,Duckworth CA,et al.Suppression of core 1 Gal-transferase is associated with reduction of TF and recipro- cal increase of Tn,sialyl- Tn and Core 3 glycans in human co-Ion cancer cells[J].PLoS One,2013,8(3):59-65.
  • 8Van Elssen CH,Frings PW, Bot FJ,et al.Expression of ab- errantly glycosylated Mucin- 1 in ovarian cancer[J].Histo- pathology,2010,57(4):597.
  • 9焦祖义.D15S128位点的STR多态性与差异甲基化联合进行亲子鉴定的研究[D].太原:山西医科大学,2010.
  • 10MORRISON J, HALDAR K, KEHOE S,et al. Chemotherapy ver- sus surgery for initial treatment in advanced ovarian epithelial cancer ~ DB/OL]. Cochrane Database Syst Rev, 2012, 8: CD005343.

引证文献19

二级引证文献107

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部